Combined General Meeting of April 2, 2024

Press release

Combined General Meeting of April 2, 2024

Paris (France) and Cambridge (Massachusetts, USA), March 18, 2024 – 7:00 A.M. CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the  development of  therapeutics  that  are  aimed  at  slowing  the  degenerative  processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, will hold its Combined General Meeting (CGM) on April 2, 2024 at 2pm at Sorbonne Université- 4 Place Jussieu, 75005 Paris.

The notice of meeting, including the agenda, the draft resolutions and the terms and conditions of attendance, was published in Bulletin des Annonces Légales Obligatoires (BALO) no. 19 of February 12, 2024, and an amending notice was published in BALO no. 24 of February 23, 2024. 

Information and preparatory documents for this General Meeting, including the voting form, are available on the Company's website (https://www.biophytis.com/en/action/assemblees-generales/biophytisannual-general-meeting-2024/)

Shareholders are strongly encouraged to vote in advance of the CGM, by (i) post, (ii) appointing the Chairman of the meeting as proxy, or (iii) via the secure online platform VOTACCESS. 

Votes must be submitted no later than three days before the general meeting (i.e. March 30, 2024) for proxy votes or postal votes and the day before for proxy votes or postal votes via VOTACCESS (i.e. April 1, 2024).

*   *   *   *

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. Ruvembri^TM, our lead drug candidate, is a small molecule in development for agerelated neuromuscular (sarcopenia and Duchenne muscular dystrophy) and cardiorespiratory (Covid-19) diseases. Promising clinical results were obtained in the treatment of sarcopenia in an international phase 2 study, enabling the launch of a phase 3 study in this indication (SARA project). The safety and efficacy of Ruvembri^TM in the treatment of severe COVID-19 were studied in a positive international phase 2-3 clinical trial (COVA project). A pediatric formulation of Ruvembri^TM is currently being developed for the treatment of Duchenne Muscular Dystrophy (DMD, MYODA project). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS ISIN: FR0012816825) and the ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040). For more information, visit www.biophytis.com

Page 1/2

Press release

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook,"  "believes,"  "expects,"  "potential,"  "continues,"  "may,"  "will,"  "should,"  "could,"   "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these   words or other comparable words. Such forward- looking statements are based on assumptions that Biophytis considers to be reasonable.  However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company’s 2022 Financial  Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information,  future developments or otherwise, except as required by law.

Biophytis contacts

Investor relations

Nicolas Fellmann, CFO

Investors@biophytis.com

Media

Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27

Nizar Berrada: nizar.berrada@taddeo.fr – +33 6 38 31 90 50

Page 2/2